Hexagon Bio Raises $77.3 Million Series B Financing and Strengthens Leadership to Expand Novel Computational Discovery Platform and Advance Microbial Genome-Derived Small Molecules Hexagon’s interdisciplinary platform enables broad opportunities across multiple therapeutic areas; company initially focused on oncology and infectious diseasesTara Arvedson, Ph.D., former Executive...